Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07044765

A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults: Fed State Study

To Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults after taking the drugs with food (fed state).

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

19 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

Chung-Ang University Gwangmyeong Hospital

Gwangmyeong, Gyeonggi-do, South Korea

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy adult volunteers aged 19 to 50 years at the time of screening.
  • Body mass index (BMI) between 18.0 and 30.0 kg/m², inclusive.
  • Male subjects must weigh ≥50 kg.
  • Female subjects must weigh ≥45 kg.
  • No clinically significant congenital or chronic diseases requiring treatment, based on medical history and physical examination.
  • Clinically acceptable results from laboratory tests (e.g., hematology, biochemistry, serology, urinalysis) and electrocardiogram (ECG) at screening, as determined by the investigator.
  • Willing to use medically accepted contraception (excluding hormonal methods) from the first dose until 7 days after the last dose, and agrees not to donate sperm or eggs during this period.
  • Able and willing to provide written informed consent after receiving a full explanation of the study.

Exclusion criteria

  • Use of drugs known to induce or inhibit drug-metabolizing enzymes within 30 days prior to the first dose, or any medication likely to interfere with the study within 10 days prior to dosing.
  • Participation in any clinical trial involving investigational products within 6 months prior to the first dose.
  • Whole blood donation within 8 weeks, or component blood donation within 2 weeks prior to the first dose.
  • History of gastrointestinal surgery that may affect drug absorption (excluding appendectomy and hernia repair).
  • History of excessive alcohol consumption within 1 month prior to the first dose:
  • >21 drinks/week for males, >14 drinks/week for females (1 drink = 50 mL soju, 30 mL whiskey, or 250 mL beer)
  • Known hypersensitivity to any component of the investigational product.
  • Clinically significant renal, hepatic, cardiovascular, respiratory, metabolic, or infectious diseases, including but not limited to:
  • Moderate to severe renal impairment (eGFR or creatinine clearance <45 mL/min)
  • Dialysis
  • Acute or unstable heart failure
  • Acute myocardial infarction, septicemia, or shock
  • Type 1 diabetes, metabolic acidosis, or history of diabetic ketoacidosis
  • Major surgery planned during the study (except minor procedures not affecting food or fluid intake)
  • Severe infections, trauma, or nutritional deficiencies
  • Positive pregnancy test or currently breastfeeding (for female subjects).
  • History of significant psychiatric illness.
  • Determined by the investigator to be unsuitable for the study for any other reason.

Treatment and study plan

Comparator 1

Drug

Dapagliflozin 10mg + Linagliptin 5mg

Comparator 2

Drug

Metformin 1000mg

Test Drug

Drug

Fixed-dose combination tablet (AJU-A53)

Primary outcomes

  1. Cmax of Metformin

    Time frame: 0 hour ~ 48 hour after drug administration

    To assess the maximum observed plasma concentration (Cmax) of Metformin

  2. AUCt of Metformin

    Time frame: 0 hour ~ 48 hour after drug administration

    To assess the plasma concentration-time curve from time 0 to the last measurable concentration (AUCt) of Metformin

Sponsors and collaborators

Lead sponsor

AJU Pharm Co., Ltd.

Industry

Registry information

Official study title

An Open-label, 2-arm, Single-sequence, Fed, Single Oral Dosing, Crossover Clinical Trial to Evaluate Safety and the Pharmacokinetics Between Dapagliflozin, Linagliptin and Metformin in Healthy Adult Subjects

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Jul 1, 2025
Registry last updated
Jul 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.